SECUADO
Peakasenapine
NDATRANSDERMALSYSTEM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
SECUADO (asenapine) is 12. First approved in 2019.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SECUADO is a transdermal patch formulation of asenapine, an atypical antipsychotic approved for bipolar I disorder. The drug acts as an antagonist across multiple serotonergic, dopaminergic, adrenergic, and histaminergic receptors, though its precise mechanism in bipolar disorder remains unknown. The sublingual/transdermal delivery system provides rapid absorption and avoids first-pass metabolism.
$5MPart D
Peak7.4 years to LOEProduct is at peak lifecycle with modest Part D penetration (3,718 claims in 2023), suggesting a niche market with stable commercial operations and smaller supporting teams.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of asenapine in bipolar I disorder is unknown. 12.2 Pharmacodynamics Asenapine exhibits high affinity for serotonin 5-HT 1A , 5-HT 1B , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 5A , 5-HT 6 , and 5-HT 7 receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.